HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Medroxyprogesterone

HCID 10631
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
520-85-4
Standard SMILES
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
InChIKey
FRQMUZJSZHZSGN-HBNHAYAOSA-N
Molecular formula
C22H32O3
Average molar mass
344.5 g/mol
Monoisotopic mass
344.23514488

Overview

Medroxyprogesterone is a 3-oxo 4-steroid that is pregn-4-ene-3,20-dione substituted by an alpha-hydroxy group at position 17 and a methyl group at position 6. It has a role as a contraceptive drug, a synthetic oral contraceptive and a progestin. It is a tertiary alpha-hydroxy ketone, a 17alpha-hydroxy steroid, a 20-oxo steroid and a 3-oxo-Delta(4) steroid.

Names & identifiers

Preferred name
Medroxyprogesterone
IUPAC
(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
English name
Medroxyprogesterone
Molecular formula
C22H32O3
Molecular weight
344.49

Names & synonyms

medroxyprogesterone520-85-4MedroxyprogesteronMedroxiprogesteronaMedroxyprogesteronumMedrossiprogesterone6alpha-Methyl-17alpha-hydroxyprogesterone17-Hydroxy-6alpha-methylprogesteroneFarlutal inyectable17alpha-Hydroxy-6alpha-methylprogesterone6alpha-Methyl-4-pregnen-17alpha-ol-3,20-dione17-Hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione
Show more names
(-)-Allantoinu8840farlutalNSC 27408Medoxyprogesterone6-DIHYDROMEGESTROLMETHYLOXYPROGESTERONEMedroxyprogesteronebase
DTXSID0036508HSU1C9YRESU 8840(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one(6alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dioneCHEBI:6715DTXCID8016508Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)-

Database identifiers

Properties

Computed structural propertiesFilling in

XLogP
3.5
Topological polar surface area
54.4 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
3
Rotatable bonds
1
Heavy atoms
25
Formal charge
0
Complexity
664

Experimental & physicochemical properties

LipidsLipids -> Sterol Lipids [ST] -> Steroids [ST02] -> C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives [ST0203]
SpringerMaterials PropertiesChemical shift
Color/FormCrystals from chloroform
Solubility · 2 items

Solubility at 25 °C: in acetone 1 in 50; slightly soluble in ether and methanol; sol at 25 °C in dioxane: 1 in 60 /Medoxyprogesteron acetate/

Very soluble in chloroform

Animal DrugsPharmaceuticals -> Animal Drugs -> Approved in Taiwan
Endocrine DisruptorsPotential endocrine disrupting compound
DecompositionWhen heated to decomposition it emits acrid smoke and irritating fumes.
Melting Point · 3 items

214.5 °C

Crystals from methanol; MW: 386.52. MP: 207-209 °C; specific optical rotation: +61 (in chloroform); uv max absorption (ethanol): 240 nm (epsilon = 15900). Freely soluble in ethanol, methanol; slightly soluble in ether; insoluble in water /Medroxyprogesterone 17-acetate/

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H361 (92.9%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

P203, P280, P318, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 42 reports by companies from 5 notifications to the ECHA C&L Inventory.

Hazard information

FDA Requirements · 1 item

The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including medroxyprogesterone acetate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Medroxyprogesterone acetate/

Hazard Classes and CategoriesRepr. 2 (92.9%)

Safety & protection

Storage Conditions · 1 item

Sterile medroxyprogesterone acetate suspensions should be stored at 20-25 °C. The sterile injectable suspension containing medroxyprogesterone acetate in fixed combination with estradiol cypionate should be stored at 25 °C, but may be exposed to temperatures ranging from 15-30deg C. Medroxyprogesterone acetate tablets should be stored in well-closed containers at 20-25 °C.

Disposal Methods · 2 items

SRP: At the time of review, regulatory criteria for small quantity disposal are subject to significant revision, however, household quantities of waste pharmaceuticals may be managed as follows: Mix with wet cat litter or coffee grounds, double bag in plastic, discard in trash.

SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

Chemistry & industry

Pharmacology

ATC Code · 6 items

G03AC06

L - Antineoplastic and immunomodulating agents

G - Genito urinary system and sex hormones

G - Genito urinary system and sex hormones

QG - Genito urinary system and sex hormones

QL - Antineoplastic and immunomodulating agents

Mechanism of Action · 5 items

Medroxyprogesterone shares the pharmacologic actions of the progestins. In women with adequate endogenous estrogen, medroxyprogesterone transforms a proliferative endometrium into a secretory one. Medroxyprogesterone has been shown to have slight androgenic activity in animals. Anabolic effects have also been reported, but the drug apparently lacks appreciable estrogenic activity in humans. In animals, the drug exhibits pronounced adrenocorticoid activity, but a clinically important effect has not been observed in humans. Medroxyprogesterone inhibits the secretion of pituitary gonadotropins following usual IM or subcutaneous dosages (eg, 150 or 104 mg every 3 months), thus preventing follicular maturation and ovulation and resulting in endometrial thinning; these effects result in contraceptive activity. Available evidence indicates that these effects do not occur following oral administration of usual dosages (ie, 5-10 mg daily as single daily doses) of the drug. High doses of medroxyprogesterone inhibit pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and will prevent cyclic gonadotropin surges that occur during the normal menstrual cycle. It has been suggested that the drug acts at the hypothalamus since it does not suppress the release of LH and FSH following administration of gonadotropin-releasing hormone and since basal concentrations of LH and FSH remain within the low normal range when the drug is used as a contraceptive. Although the mechanism of action has not been determined, medroxyprogesterone has antineoplastic activity against some cancers (eg, endometrial carcinoma, renal carcinoma).

Progestins elicit, to varying degrees, all the pharmacologic responses usually produced by progesterone: induction of secretory changes in the endometrium, increase in basal body temperature (thermogenic action), production of histologic changes in vaginal epithelium, relaxation of uterine smooth muscle, stimulation of mammary alveolar tissue growth, pituitary inhibition, and production of withdrawal bleeding in the presence of estrogen. /Progestins/

Following binding to cytoplasmic receptor protein, steroid is transported to nucleus, and complex is bound there in reactions analogous to those described... for estrogens. However, there is no apparent need for receptor alteration, as with estrogen receptor. /Progesterone/

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
CAS
520-85-4
PubChem CID
10631
DTXSID
DTXSID0036508
ChEMBL
CHEMBL1390
ChEBI
CHEBI:6715
UNII
HSU1C9YRES
EC Number
208-298-6
Nikkaji
J6.606K

214.5 °C

Optical Rotation · 2 items

Specific optical rotation: +75 deg at 25 °C/D (in chloroform)

SPECIFIC OPTICAL ROTATION: +51 DEG (IN DIOXANE)

Physical DescriptionSolid
Stability/Shelf LifeStable in air. /Acetate/
Other Experimental PropertiesWhite to off-white, crystalline powder, odorless. Melting range 200-208 °C. Stable in air. Freely soluble in chlorform. /Medroxyprogesterone acetate/

Physicochemical properties

Melting point
204 · 204-206°C
alpha
25 · D25 +75° (in chloroform)
Boiling point
419.57 °C · 419.57°C (rough estimate)
Density
1.0906 · 1.0906 (rough estimate)
refractive index
1.5 · 1.5000 (estimate)
storage temp.
Sealed in dry,Room Temperature
solubility
Chloroform (Slightly), Methanol (Slightly)
form
Solid
pka
13.03 · 13.03±0.70(Predicted)
color
White
Merck
13 · 13,5817
BRN
2510965 · 2510965
Henry's Law Constant
7.6 · 7.6×102 mol/(m3Pa) at 25℃, HSDB (2015)
InChI
1S/C22H32O3/c1-13-11-16-17(20(3)8-5-15(24)12-19(13)20)6-9-21(4)18(16)7-10-22(21,25)14(2)23/h12-13,16-18,25H,5-11H2,1-4H3/t13-,16+,17-,18-,20+,21-,22-/m0/s1
InChIKey
FRQMUZJSZHZSGN-HBNHAYAOSA-N
SMILES
C1[C@@]2(C)C([C@H](C[C@]3([H])[C@]2([H])CC[C@@]2(C)[C@@]3([H])CC[C@@]2(C(C)=O)O)C)=CC(=O)C1
CAS DataBase Reference
520 · 520-85-4(CAS DataBase Reference)
FDA UNII
1 C9YRES · HSU1C9YRES
ATC code
3 AC06,G03DA02,L02AB02 · G03AC06,G03DA02,L02AB02
EPA Substance Registry System
Medroxyprogesterone (520-85-4)
UNSPSC Code
51111800 · 51111800
NACRES
77 · NA.77
Symbol(GHS)
8 · GHS08
Signal word
Warning
Hazard statements
361 · H361
Precautionary statements
280 · P280
PPE
3 · Eyeshields, Gloves, type P3 (EN 143) respirator cartridges
Hazard Codes
Xn
Risk Statements
48 · 48-63-68
Safety Statements
22 · 22-24/25
WGK Germany
3 · 3
RTECS
5300000 · TU5300000
HS Code
29372390 · 29372390
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
2 · Repr. 2
Hazardous Substances Data
520 · 520-85-4(Hazardous Substances Data)

Toxicology

Interactions · 3 items

Sequential conversion of estradiol (E) to 2/4-hydroxyestradiols and 2-/4-methoxyestradiols (MEs) by CYP450s and catechol-O-methyltransferase, respectively, contributes to the inhibitory effects of E on smooth muscle cells (SMCs) via estrogen receptor-independent mechanisms. Because medroxyprogesterone (MPA) is a substrate for CYP450s, /investigators/ hypothesized that MPA may abrogate the inhibitory effects of E by competing for CYP450s and inhibiting the formation of 2/4-hydroxyestradiols and MEs. To test this hypothesis, /the authors/ investigated the effects of E on SMC number, DNA and collagen synthesis, and migration in the presence and absence of MPA. The inhibitory effects of E on cell number, DNA synthesis, collagen synthesis, and SMC migration were significantly abrogated by MPA. For example, E (0.1micromol/L) reduced cell number to 51+/-3.6% of control, and this inhibitory effect was attenuated to 87.5+/-2.9% by MPA (10 nmol/L). Treatment with MPA alone did not alter any SMC parameters, and the abrogatory effects of MPA were not blocked by RU486 (progesterone-receptor antagonist), nor did treatment of SMCs with MPA influence the expression of estrogen receptor-alpha or estrogen receptor-beta. In SMCs and microsomal preparations, MPA inhibited the sequential conversion of E to 2-2/4-hydroxyestradiol and 2-ME. Moreover, as compared with microsomes treated with E alone, 2-ME formation was inhibited when SMCs were incubated with microsomal extracts incubated with E plus MPA. /These/ findings suggest that the inhibitory actions of MPA on the metabolism of E to 2/4-hydroxyestradiols and MEs may negate the cardiovascular protective actions of estradiol in postmenopausal women receiving estradiol therapy combined with administration of MPA.

Medroxyprogesterone acetate (MPA) ... is extensively metabolized in the intestinal mucosa and in the liver. Cytochrome P450s (CYPs) involved in the metabolism of MPA were identified by using human liver microsomes and recombinant human CYPs. In this study, the overall metabolism of MPA was determined as the disappearance of the parent drug from an incubation mixture. The disappearance of MPA in human liver microsomes varied 2.6-fold among the 18 samples studied. The disappearance of MPA in the same panel of 18 human liver microsomes was significantly correlated with triazolam alpha-hydroxylase activity, a marker activity of CYP3A (r = 0.764; P < 0.001). Ketoconazole, an inhibitor of CYP3A4, potently inhibited the disappearance of MPA in 18 human liver microsomes. Anti-CYP3A antibody also inhibited 86% of the disappearance of MPA in human liver microsomes. Although sulfaphenazole (an inhibitor of CYP2C9) and S-mephenytoin (an inhibitor of CYP2C19) partially inhibited the disappearance of MPA, no effect of the anti-CYP2C antibody was observed. The disappearance of MPA did not correlate with either the activity metabolized via CYP2C9 (diclofenac 4'-hydroxylase activity) or the activity metabolized via CYP2C19 (S-mephenytoin 4'-hydroxylase activity). Among the 12 recombinant human CYPs (CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5) studied, only CYP3A4 showed metabolic activity of MPA. These results suggest that CYP3A4 is mainly involved in the overall metabolism of MPA in human liver microsomes.

This report describes a fatal pneumonitis occurring in a breast cancer patient while on adjuvant treatment with radiotherapy and medroxyprogesterone acetate. The clinical and radiologic features, as well as the timing of this pneumonitis, make a radiation pneumonitis more than probable. A radiation pneumonitis was also observed in other patients treated in the same way. Medroxyprogesterone acetate thus seems to act as a radiosensitizer since no such effects were seen in patients treated with radiotherapy alone. The radioenhancing effect is not limited to the lungs, since radioesofagitis was also encountered in similarly treated patients.

Environmental Fate · 3 items

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 1,200(SRC), determined from a structure estimation method(2), indicates that medroxyprogesterone is expected to have low mobility in soil(SRC). Volatilization of medroxyprogesterone from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 1.3X10-8 atm-cu m/mole(SRC), using a fragment constant estimation method(3). Medroxyprogesterone is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.9X10-10 mm Hg at 25 °C(SRC), determined from a fragment constant method(4). Biodegradation data in soil were not available(SRC, 2011).

AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 1,200(SRC), determined from a structure estimation method(2), indicates that medroxyprogesterone is expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 1.3X10-8 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). According to a classification scheme(5), an estimated BCF of 94(SRC), from an estimated log Kow of 3.50(6) and a regression-derived equation(7), suggests the potential for bioconcentration in aquatic organisms is moderate(SRC). Biodegradation data in water were not available(SRC, 2011).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), medroxyprogesterone, which has an estimated vapor pressure of 1.9X10-10 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase medroxyprogesterone may be removed from the air by wet or dry deposition(SRC). Medroxyprogesterone contains chromophores that absorb at wavelengths >290 nm(3), and therefore may be susceptible to direct photolysis by sunlight(SRC).

Adverse Effects · 1 item

Menstrual irregularities and weight gain are the most common adverse effects of medroxyprogesterone. Regarding weight gain, a study reported that medroxyprogesterone use increased by 1.61 in BMI and an average weight gain of 3.23 kg (7.11 lb). Meanwhile, 57.3% of the patients receiving medroxyprogesterone reported irregular menses during the first year. Irregular bleeding decreases to 30% after 24 months and 10% after 24 months. Fifty-five percent of women report amenorrhea after 12 months of therapy, increasing to 68% after 2 years.

Milk Concentrations · 1 item

Radioimmunoassay methods were used estimating contraceptive levels in breast milk and plasma samples in 7 lactating women after injection of 150 mg medroxyprogesterone acetate. Levels in breast milk were similar to plasma; ratio being almost 1:1 up to 87 days.

Toxicity SummaryPatients experiencing medroxyprogesterone overdose may experience nausea, vomiting, seizures, trouble breathing, and altered mental status. Treatment is primarily supportive.
Effluent Concentrations · 1 item

Medroxyprogesterone was reported in 14% of 95-144 samples of central California municipal waste water treatment plant effluent with a maximum concentration of 14.9 ng/L(1). It was not detected in a typical dairy waste disposal system for 2000 dairy cows in San Jacinto, CA; samples include fresh manure less than 2 hrs old, piled manure at 2 weeks, and 3 lagoon dams at 3 months(2).

Soil Adsorption/Mobility · 1 item

Using a structure estimation method based on molecular connectivity indices(1), the Koc of medroxyprogesterone can be estimated to be 1,200(SRC). According to a classification scheme(2), this estimated Koc value suggests that medroxyprogesterone is expected to have low mobility in soil.

Human Toxicity Excerpts · 5 items

/HUMAN EXPOSURE STUDIES/ When medroxyprogesterone is used as a contraceptive, unintended pregnancies that occur within 1-2 months after IM injection of the drug may be characterized by impaired fetal growth as evidenced by low birthweights, which theoretically could result in an increased risk of neonatal death. However, the attributable risk of this adverse effect is low because such pregnancies are unlikely. The risk of low birthweight was particularly evident when conception was estimated to occur within 4 weeks of medroxyprogesterone injection. ... An increase in polysyndactyly particularly among offspring of women younger than 30 years of age, and chromosomal anomalies also have been observed in neonates born to women who received IM medroxyprogesterone contraception.

/HUMAN EXPOSURE STUDIES/ Milk quality and quantity was studied in 6 breast feeding women admin 150 mg depomedroxyprogesterone acetate im every 3 months. The drug was associated with a decrease in concentration of protein in milk.

/HUMAN EXPOSURE STUDIES/ ...The purpose of this study was to determine the acute effects of MPA when used in combination with estradiol on markers of cardiovascular risk in young women. /The authors/ suppressed endogenous estrogens and progesterone in 10 premenopausal women using a gonadotropin-releasing hormone antagonist (GnRHa) for 10 days. On day 4 of GnRHa subjects received 0.1 mg of estradiol (GnRHa+E(2)), and on day 7 5 mg of MPA was added (GnRHa+E(2)+MPA). Endothelium-dependent vasodilation and endothelium-independent vasodilation of the brachial artery, lipids, homocysteine, high-sensitivity C-reactive protein, and endothelin-1 were assessed during treatment with GnRHa, GnRHa+E(2), and GnRHa+E(2)+MPA. Four additional subjects were tested to validate the efficacy of the GnRHa model and confirm the findings. Endothelium-dependent vasodilation was greater during GnRHa+E(2) than during GnRHa or GnRHa+E(2)+MPA (P = 0.006). Endothelin-1 was lower during GnRHa+E(2) than GnRHa alone (P = 0.039). Endothelin-1 increased with the addition of MPA and was not significantly different from GnRHa alone. There were no differences in the other markers of cardiovascular risk between hormone treatment days. These data suggest that acute MPA administration negates the beneficial effects of estradiol on endothelium-dependent vasodilation in young women. In addition, these data suggest that estradiol decreases endothelin-1 concentrations and the addition of MPA may counteract the effect of estradiol on endothelin-1.

/SIGNS AND SYMPTOMS/ Overdosage of estrogen plus progestin therapy may cause nausea and vomiting, breast tenderness, dizziness, abdominal pain, drowsiness/fatigue and withdrawal bleeding may occur in women. Treatment of overdose consists of discontinuation of CE/MPA together with institution of appropriate symptomatic care.

For more Human Toxicity Excerpts (Complete) data for MEDROXYPROGESTERONE (26 total), please visit the HSDB record page.

Artificial Pollution Sources · 1 item

Medroxyprogesterone's production and use as a progestogen, injectable contraceptive, and hormonal antineoplastic in humans and also as an estrus regulator in veterinary medicine(1) may result in its release to the environment through various waste streams(SRC).

Environmental Bioconcentration · 1 item

An estimated BCF of 94 was calculated in fish for medroxyprogesterone(SRC), using an estimated log Kow of 3.50(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is moderate(SRC).

Volatilization from Water/Soil · 1 item

The Henry's Law constant for medroxyprogesterone is estimated as 1.3X10-8 atm-cu m/mole(SRC) using a fragment constant estimation method(1). This Henry's Law constant indicates that medroxyprogesterone is expected to be essentially nonvolatile from water surfaces(2). Medroxyprogesterone's Henry's Law constant indicates that volatilization from moist soil surfaces may not occur(SRC). Medroxyprogesterone is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.9X10-10 mm Hg(SRC), determined from a fragment constant method(3).

Non-Human Toxicity Excerpts · 5 items

/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ A group of virgin female BALB/c mice, eight weeks of age, was divided into three subgroups: 44 received 60 mg progesterone, as 40 mg in a Silastic pellet implanted subcutaneously initially and 20 mg six months later; 45 received 60 mg medroxyprogesterone acetate, as a 40-mg pellet initially and 20 mg six months later; and 47 received 160 mg of the progestogen, 40 mg subcutaneously every three months for one year, representing the protocol used in the development of this model. The incidence of mammary adenocarcinoma and the numbers and latency of the tumours are shown in/the/ table /provided/. The carcinomas induced by medroxyprogesterone acetate were predominantly ductal but included some lobular carcinomas. The incidence of mammary carcinomas in untreated controls was reported previously to be 0/42 at 80-90 weeks of age.

/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Female BALB/c mice, two months of age, were either left intact or sialoadenectomized. One month after sialoadenectomy, all mice were injected subcutaneously with 40 mg depot medroxyprogesterone acetate, and the same treatment was given every three months for one year. The incidence of ductal and lobular mammary adenocarcinomas in the intact mice was 34/47, and that in the sialoadenectomized group was significantly less (11/48; p < 0.001). The tumor latency was similar: 52.5 +/-3.8 and 50.1 +/- 2.1 weeks, respectively.

/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Groups of 20 virgin beagle bitches were hysterectomized at four to six months of age and given medroxyprogesterone acetate intramuscularly as an aqueous suspension, at a dose of 0 (control), 30, 180 or 690 mg every three months for 48 months, corresponding to one, six and 23 times the human contraceptive dose. As shown in /the/ table /provided/, the incidence of mammary tumor nodules was increased in treated animals. Histopathological examination of the nodules revealed the presence of hyperplasia, including 13 animals at the high dose with complex lobular hyperplasias. At that dose, the tumor type was predominantly (12/14) complex adenoma. No carcinomas were detected.

/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Two groups of seven elderly beagle bitches weighing 10-15 kg (median ages, 7 and 6.8 years) that had not previously been treated with progestogens were subjected to surgical ovariohysterectomy to eliminate endogenous progesterone. Four to six weeks later, depot medroxyprogesterone acetate (10 mg/kg bw) or proligestone (50 mg/kg bw) was administered subcutaneously at three-week intervals for a total of eight injections. Four to eight weeks after the last injection, three dogs per group were killed for analysis of tissues, and the remaining four per group were maintained for six months without additional progestogen treatment. After this time, treatment was resumed at the same intervals, for a total of five more injections. The dogs were killed five to eight weeks later. Four dogs served as untreated controls; no abnormalities were found in any organ. The most frequent changes in the progestogen-treated dogs were adrenal atrophy (6/7 receiving medroxyprogesterone acetate and 7/7 receiving proligestone) and benign mammary tumors (5/7 receiving medroxyprogesterone acetate and 5/7 receiving proligestone). Some hepatic and pancreatic toxicity was also observed.

Regulatory information

FDA Requirements · 1 item

The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including medroxyprogesterone acetate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Medroxyprogesterone acetate/

Safety data

PPE
Eyeshields, Gloves, type P3 (EN 143) respirator cartridges
wgk
3
rtecs
TU5300000
hs_code
29372390
risk_code
48-63-68
Signal word
Warning
Symbol(GHS)
GHS08
hazard_code
Xn
safety_code
22-24/25
Storage Class
11 - Combustible Solids
Hazard statements
H361
Hazard Classifications
Repr. 2
Precautionary statements
P280
Hazardous Substances Data
520-85-4(Hazardous Substances Data)

Although medroxyprogesterone acetate (MPA) is used as an injectable contraceptive, in hormone replacement therapy (HRT) and in treatment of certain cancers, the steroid receptors and their target genes involved in the actions of MPA are not well understood. /Investigators/ show that MPA, like dexamethasone (dex), significantly represses tumour necrosis factor (TNF)-stimulated interleukin-6 (IL-6) protein production in mouse fibroblast (L929sA) cells. In addition, MPA repressed IL-6 and IL-8 promoter-reporter constructs at the transcriptional level, via interference with nuclear factor kappaB (NFkappaB) and activator protein-1 (AP-1). Furthermore, like dex, MPA does not affect NFkappaB DNA-binding activity. /The authors/ also observed significant transactivation by MPA of a glucocorticoid response element (GRE)-driven promoter-reporter construct in both L929sA and COS-1 cells. The MPA-induced nuclear translocation of the glucocorticoid receptor (GR), as well as the antagonistic effects of RU486, strongly suggest that the actions of MPA in these cells are mediated at least in part via the GR.

/Investigators/ assessed the transcriptional effects of MPA as compared with those of progesterone and dihydrotestosterone (DHT) in human breast cancer cells. A new progesterone receptor-negative, androgen receptor-positive human breast cancer cell line, designated Y-AR, was engineered and characterized. Transcription assays using a synthetic promoter/reporter construct, as well as endogenous gene expression profiling comparing progesterone, MPA and DHT, were performed in cells either lacking or containing progesterone receptor and/or androgen receptor. In progesterone receptor-positive cells, MPA was found to be an effective progestin through both progesterone receptor isoforms in transient transcription assays. Interestingly, DHT signaled through progesterone receptor type B. Expression profiling of endogenous progesterone receptor-regulated genes comparing progesterone and MPA suggested that although MPA may be a somewhat more potent progestin than progesterone, it is qualitatively similar to progesterone. To address effects of MPA through androgen receptor, expression profiling was performed comparing progesterone, MPA and DHT using Y-AR cells. These studies showed extensive gene regulatory overlap between DHT and MPA through androgen receptor and none with progesterone. Interestingly, there was no difference between pharmacological MPA and physiological MPA, suggesting that high-dose therapeutic MPA may be superfluous. /This/ comparison of the gene regulatory profiles of MPA and progesterone suggests that, for physiologic hormone replacement therapy, the actions of MPA do not mimic those of endogenous progesterone alone. ... It is possible that the increased breast cancer risk and/or the therapeutic efficacy of MPA in cancer treatment is in part mediated by androgen receptor.

Biological Half-LifeElimination half-life of oral preparation is 32 to 44 hr. /Acetate/
Metabolism/Metabolites · 1 item

Following oral dosing, MPA is extensively metabolized in the liver via hydroxylation, with subsequent conjugation and elimination in the urine. ...MPA is almost exclusively eliminated via hepatic metabolism. In 14 patients with advanced liver disease, MPA disposition was significantly altered (reduced elimination). In patients with fatty liver, the mean percent dose excreted in the 24-hour urine as intact MPA after a 10 mg or 100 mg dose was 7.3% and 6.4%, respectively.

FDA Pharmacological Classification · 6 items

HSU1C9YRES

MEDROXYPROGESTERONE

Chemical Structure [CS] - Progesterone Congeners

Established Pharmacologic Class [EPC] - Progestin

Medroxyprogesterone is a Progestin.

MEDROXYPROGESTERONE

MeSH Pharmacological Classification · 2 items

Oral contraceptives which owe their effectiveness to hormonal preparations.

Oral contraceptives which owe their effectiveness to synthetic preparations.

Absorption, Distribution and Excretion · 5 items

No specific investigation on the absolute bioavailability of medroxyprogesterone (MPA) in humans has been conducted. MPA is rapidly absorbed from the gastrointestinal tract, and maximum MPA concentrations are obtained between 2 to 4 hours after oral administration.

Administration of medroxyprogesterone acetate with food increases the bioavailability of MPA. A 10 mg dose of medroxyprogesterone acetate, taken immediately before or after a meal, increased MPA Cmax (50 to 70%) and AUC (18 to 33%). The half-life of MPA was not changed with food.

Medroxyprogesterone is approximately 90% protein bound, primarily to albumin; no MPA binding occurs with sex hormone binding globulin.

Most MPA metabolites are excreted in the urine as glucuronide conjugates with only minor amounts excreted as sulfates.

For more Absorption, Distribution and Excretion (Complete) data for MEDROXYPROGESTERONE (10 total), please visit the HSDB record page.

Cellular LocationsExtracellular

Uses & manufacturing

Uses · 4 items

THERAPEUTIC CATEGORY (VETERINARY): Progestogen; estrus regulator

MEDICATION

MEDICATION (VET)

Use (kg; approx.) in Germany (2009): >250

Impurities · 1 item

Reported impurities include: 6alpha,17a-dimethyl-3,17-dioxo-D-homoandrost-4-en-17aalpha- yl acetate, 6beta-hydroxy-6-methyl-3,20-dioxopregn-4-en-17-yl acetate (6beta-hydroxymedroxyprogesterone acetate), 17-hydroxy-6alpha-methylpregn-4-ene-3,20-dione (medroxyprogesterone), 6-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate, 6alpha-methyl-3,20-dioxo-5beta-pregnan-17-yl acetate (4,5beta-dihydromedroxyprogesterone acetate), 6beta-methyl-3,20-dioxopregn- 4-en-17-yl acetate (6-epimedroxyprogesterone acetate) and 6-methylene-3,20-dioxopregn- 4-en-17-yl acetate. /Medroxyprogesterone acetate/

Methods of Manufacturing · 2 items

From 17alpha-hydroxyprogesterone by first forming the 3,21-bisethylene acetal with ethylene glycol, then treating with peracetic acid to give a mixture of the 5alpha,6alpha- and 5beta,6beta-epoxides. With methyl magnesium iodide the alpha-epoxide isomer yields the 5alpha-hydroxy-6beta-methyl derivative, which dehydrates and epimerizes with hydrogen chloride in chloroform to the delta4-6alpha-methyl compound, medroxyprogesterone. Acylation with acetic anhydride and p-toluenesulfonic acid in acetic acid gives medroxyprogesterone acetate.

The bisethylene acetal of 17alpha-hydroxyprogesterone was treated with peracetic acid to give a mixture of 5alpha,6alpha-epoxy-17alpha-hydroxypregnane-3,20-dione bisethylene acetal and the corresponding 5beta,6beta-epoxide. The 5alpha,6alpha-epoxide was refluxed with methylmagnesium bromide in tetrahydrofuran to afford the bisethylene acetal of 5alpha,17alpha- dihydroxy-6beta-methylpregnane-3,20-dione. Dehydration by dilute sodium hydroxide in pyridine produced 6beta-methyl-17alpha-hydroxyprogesterone which was epimerized in chloroform saturated with gaseous hydrogen chloride to 6alpha-methyl-17alpha-hydroxyprogesterone. Alternatively, dehydration and epimerization of 5alpha,17beta-dihydroxy-6beta-methylpregnane- 3,20-dione bisethylene acetal could be effected directly with chloroform or hydrogen chloride. Acylation with acetic anhydride, acetic acid and para-toluenesulfonic acid produced medroxyprogesterone acetate. /Medroxyprogesterone acetate/

Formulations/PreparationsMedroxyprogesterone acetate is available commercially as single-ingredient tablets, as combination tablets with conjugated estrogens, estradiol or estradiol cypionate and as sterile suspensions. /Medroxyprogesterone acetate/
Use ClassificationPharmaceuticals -> Animal Drugs -> Approved in Taiwan
General Manufacturing Information · 3 items

...Used in human medicine in US for treatment of endometriosis, habitual abortion and threatened abortion. ...in Oct 1973 US Food & Drug Administration announced plans to withdraw approval for certain strengths and vial sizes ... destined for these applications ... /Medroxyprogesterone acetate/

...In Oct 1973 US Food & Drug Administration proposed to restrict approved uses of medroxyprogesterone acetate tablets to treatment of endometriosis, secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance, in absence of organ pathology such as submucous fibroids or uterine cancer... /Medroxyprogesterone acetate/

From 1964 until late 1970...product was withdrawn from US market, medroxyprogesterone acetate was used in us as component of oral contraceptives. ... Product was removed...because studies showed that breast nodules developed in beagles given high doses of medroxyprogesterone acetate. /Medroxyprogesterone acetate/

Applications

UsesAn orally active progestogen used in hormone replacement therepy (HRT), in the past has been used as a component of oral contraceptives.SMedroxyprogesterone Acetate USP Related Compound B.

UsesMEDROXYPROGESTERONE is an orally active progestogen used in hormone replacement therepy (HRT), in the past has been used as a component of oral contraceptives.

Upstream & downstream products

Upstream raw materials

Acetic anhydridePeroxyacetic acidSulfuric acidMethylmagnesium BromideEthylene glycolPregnane-3,20-dione, 5,17-dihydroxy-6-methyl-, (5α,6β)-6β-Medroxyprogesterone3-beta,17-alpha-dihydroxypregn-5-en-20-one 3-acetate6-Methyl-17α-hydroxy pregnenolone diacetate)Medroxyprogesterone Acetate17-hydroxypregn-5-ene-3,20-dione cyclic bis(ethylene acetal)(5α,6α)-Epoxy-17α-hydroxy-pregnane-3,20-dione-3,20-bis(ethyleneketal)

Additional notes

DefinitionChEBI: A 3-oxo Delta4-steroid that is pregn-4-ene-3,20-dione substituted by an alpha-hydroxy group at position 17 and a methyl group at position 6.

For more Non-Human Toxicity Excerpts (Complete) data for MEDROXYPROGESTERONE (19 total), please visit the HSDB record page.